Nordson Corporation (NDSN) - 10-K Summary
Business Context and Reporting Period
Company: Nordson Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: October 31, 2025
Business Overview: Nordson is a global precision technology company engineering, manufacturing, and marketing products for dispensing, applying, and controlling fluids, as well as testing and inspecting quality. The company operates through three segments: Industrial Precision Solutions (IPS), Medical and Fluid Solutions (MFS), and Advanced Technology Solutions (ATS). Approximately 67% of revenues are generated outside the United States.
Key Financial Metrics (Fiscal Year 2025)
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Sales | $2,791,687 | $2,689,921 | +3.8% |
| Gross Margin | $1,539,784 | $1,486,129 | +3.6% |
| Gross Margin % | 55.2% | 55.2% | 0.0% |
| Operating Profit | $711,725 | $674,001 | +5.6% |
| Net Income | $484,474 | $467,284 | +3.7% |
| Diluted EPS | $8.51 | $8.11 | +5.0% |
| Operating Cash Flow | $719,175 | $556,193 | +29.3% |
| Cash & Equivalents | $108,442 | $115,952 | -6.5% |
| Total Debt (Long-term + Current) | $2,000,000 | $2,223,928 | -10.1% |
Note: All amounts in thousands except per share data.
Material Changes vs. Prior Period
- Revenue Growth: Total sales increased 3.8% driven by acquisitions (6.0% impact) and currency (0.3% impact), partially offset by a 2.5% decline in organic sales.
- Segment Performance:
- IPS: Sales declined 4.8% (organic -5.1%) due to weakness in polymer processing and industrial coatings.
- MFS: Sales increased 20.1% primarily due to the Atrion acquisition (23.0% impact), despite a 3.1% organic decline from the divestiture of medical contract manufacturing.
- ATS: Sales increased 4.9% driven by organic growth of 4.1% in electronics dispense and optical sensors.
- Profitability: Operating profit rose 5.6% to $711.7 million. Segment EBITDA margins improved in MFS (+40 bps) and ATS (+180 bps), while IPS declined slightly (-10 bps).
- Divestiture Charges: The company recorded $12.5 million in divestiture and related charges in 2025 associated with exiting the medical contract manufacturing business.
- Interest Expense: Increased 20.3% to $101.1 million due to higher average debt levels funding acquisitions.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted strong cash flow generation, utilizing proceeds to repurchase over $300 million in common shares and reduce debt by approximately $224 million. The company remains focused on the "Ascend" strategy to deliver top-tier growth with leading margins.
Risks and Contingencies:
- Geopolitical & Trade: Conflicts in Europe and the Middle East, along with U.S. trade policy changes (tariffs), create uncertainty for global supply chains and costs.
- Currency: Significant exposure to foreign currency fluctuations (Euro, Yen, Pound, Yuan) impacts reported results.
- Acquisition Integration: Risks associated with integrating recent acquisitions (Atrion, ARAG) and realizing expected synergies.
- Cybersecurity: Ongoing threats to IT systems and data privacy, though no material incidents were reported in 2025.
Key Facts for Investor Verification
- Share Repurchases: Verify the remaining authorization of approximately $724 million for share repurchases as of October 31, 2025.
- Debt Covenants: Confirm continued compliance with leverage and interest coverage ratios under the $1.15 billion credit facility.
- Goodwill Valuation: Review the annual goodwill impairment test results (August 1, 2025) which indicated no impairment, with fair value exceeding carrying value by significant margins (e.g., 311% for IPS).
- Divestiture Impact: Assess the long-term impact of exiting the medical contract manufacturing business on the MFS segment's organic growth trajectory.
- Tax Legislation: Monitor the impact of the "One Big Beautiful Bill Act" (signed July 4, 2025) on future effective tax rates, as effects were not reflected in the 2025 financials.